Low-dose chemotherapy combination for advanced pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a new combination of chemotherapy drugs for people with stage IV pancreatic cancer that has not responded to previous treatment. It aims to see if this combination can help control the cancer and improve survival.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage IV pancreatic cancer that has spread to other parts of the body
- You have already tried one type of chemotherapy and it did not work
- You are physically able to care for yourself and are not bedridden
- You are expected to live at least 3 more months
- Your organs (like kidneys, liver) are working well enough for this treatment
- You are 18 years or older
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs and radiation for people with pancreatic cancer that has spread. It aims to shrink tumors and improve quality of life by using an immunotherapy drug, two chemotherapies, and precisely targeted radiation.
This trial tests a new targeted drug (LM-302) combined with a standard chemotherapy drug (gemcitabine) for people with advanced pancreatic cancer that has progressed after initial treatment. The goal is to see if this combination can slow down or shrink the cancer.
This trial tests a new combination of drugs (NC410 plus chemotherapy and nivolumab, with or without ipilimumab) for people with metastatic pancreatic cancer who haven't had treatment yet. The goal is to see if adding these immunotherapy agents can help shrink or control the tumor.
This trial tests whether adding the diabetes drug canagliflozin to a standard chemotherapy medicine (gemcitabine) can help treat advanced pancreatic cancer. The goal is to see if this combination can shrink tumors or improve survival.
This trial tests a new immunotherapy drug called ivonescimab combined with chemotherapy, with or without another experimental drug (AK117), for people with pancreatic cancer that has spread. The goal is to see if adding these therapies can help shrink tumors or slow the cancer's growth.
This trial tests a new medicine (FG-M108) combined with chemotherapy for pancreatic cancer that is advanced or has spread. The medicine targets a protein found on some pancreatic cancer cells, and the goal is to see if it helps shrink tumors or slow the cancer more than chemotherapy alone.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.